Metal- and redox homeostasis in prostate cancer with vitamin D3 supplementation by Süle K et al.
Contents lists available at ScienceDirect
Biomedicine & Pharmacotherapy
journal homepage: www.elsevier.com/locate/biopha
Metal- and redox homeostasis in prostate cancer with vitamin D3
supplementation
Krisztina Sülea,b,⁎, Klára Szentmihályia, Gergő Szabób, Dénes Kleinerb, Imre Vargac, Anna Egresib,
Zoltán Maya, Péter Nyirádyd, Miklós Mohai Jr.e, Anna Blázovicsb
a Institute of Materials and Environmental Chemistry, Research Centre for Natural Sciences of the Hungarian Academy of Sciences, Magyar Tudósok körútja 2, H-1117
Budapest, Hungary
b Institute of Farmacognosy Semmelweis University, Üllői út 26, H-1086 Budapest, Hungary
cMedical Center of Dunakeszi, Fő út 75-86, H-2120 Dunakeszi, Hungary
d Department of Urology and Urooncological Centre, Semmelweis University, Üllői út 78/b, H-1082 Budapest, Hungary
e Budapest University of Technology and Economics, Műegyetem rkp. 3, H-.1111 Budapest, Hungary
A R T I C L E I N F O
Keywords:
Micro-macro elements
prostate cancer
vitamin D3
ICP-OES
A B S T R A C T
Vitamin D3 supplementation has a beneﬁcial eﬀect on cancerous patients, although it can inﬂuence the redox-
and metal homeostasis. The aim of our investigation was to demonstrate the eﬀect of vitamin D3 consumption on
the redox- and metal homeostasis in prostate cancer, because of the recommended daily dose increased from 200
IU to 2000 IU in recent years in Hungary. Forty-three volunteers were involved in the study. The grouping was
applied according to the clinical routine laboratory parameters (vitamin D3) and the tumor markers (PSA, fPFA).
Patients were divided into 5 groups: (A) patient control (N=8), (B) patient control with vitamin D3 treatment
(N=9), (C) high-risk prostate cancer group (N=6), (D) high-risk prostate cancer group with vitamin D3
treatment (N=8) and (E) vitamin D3 treated cancerous group with androgen deprivation therapy (N=11). The
element concentrations were determined with ICP-OES. Among the redox parameters, free radical scavenging
capacity and H-donating ability were determined with luminometry and spectrometry. Vitamin D3 treatment
caused diﬀerences in the metal- and redox homeostasis in either patient control and cancerous groups. The
concentration of Fe, Cr, and Pb signiﬁcantly increased in the erythrocytes of prostate cancer patients. According
to the higher scavenging capacity by vitamin D3 treatment, it seems that vitamin D3 helps to equilibrate the
redox homeostasis that could aﬀect the outcome of cancer positively. However, the tendency in the metal ele-
ment status does not give a clear explanation of cancer's outcome, but the accumulation of Pb by vitamin D3
supplementation needs to be taken into more serious consideration in set terms of occupational diseases.
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1. Introduction
In the literature, there are a few investigations about the eﬀect of
vitamin D3 against oxidative stress, but they show positive results, be-
cause vitamin D3 increases the SOD activity, reverses the alteration in
the oxidative and nitrosative stress parameters [1]. Epidemiological
studies indicate that vitamin D3 (1α,25(OH)2D3) deﬁciency is an im-
portant factor in various human cancer type [2–4]. In Europe, prostate
cancer is one of the most commonly diagnosed malignant diseases
among men after non-melanoma skin cancer, colorectal and lung cancer
whose mortality increases with age. Besides genetic diversity and ad-
verse environmental aspects, vitamin D3 deﬁciency plays an important
role in the incidence of prostate cancer. Clinical researches and mole-
cular studies have already established that vitamin D3 inhibits cell
proliferation on androgen receptor (AR)-positive and AR-negative in
the prostate tumor cells. Antiproliferative eﬀect of vitamin D3 is
mediated by the vitamin D receptor (VDR), as calcitriol (1α,25(OH)2D)
binds to VDR, and it interacts with the retinoid X receptor (RXR) [5,6].
Several forms of cholecalciferol could be bound to the vitamin D3 re-
ceptor, but 1,25-dihydroxycholecalciferol is biologically more potent
due to its 1000 times higher aﬃnity to VDR than that of to 25-hydro-
xycholecalciferol [7]. Nevertheless, a hormonally active form of vi-
tamin D3 (25-dihydroxycholecalciferol) activates the apoptotic path-
ways through the expression of p53 tumor suppressor protein,
modulates cell cycle by inhibition of the G1–S transition and inhibits
cell diﬀerentiation in tumors through the signal transduction processes
[8–10]. In vitro studies on human prostate cancer cell lines and mouse
models have demonstrated that vitamin D3 and its derivatives can in-
hibit the growth of cancer cells, by inducing apoptosis and preventing
cell proliferation [11–14]. Also, vitamin D secosteroids can activate
cyclin-dependent kinase inhibitors, e.g. INK4 proteins, p21waf1, and
p27kip1 [15].
With these ﬁndings, it is highly considered that the treatment of
vitamin D3 and its analogs could be used as alternative therapy in
prostate cancer.
There are still not enough indicators available to diagnose prostate
cancer at an early stage and diﬀerentiate the patients who require
prostatectomy or oncological treatment for healing. Even the level of
prostate-speciﬁc antigen (PSA), whose height is the most common sign
of the disease occurrence, can stay within the normal range or give a
false negative result, especially at the early stage. Several studies were
carried out to ﬁnd a speciﬁc biomarker of the redox system to de-
termine the disease severity. Some studies in human tumor cell lines
refer to the increase of interleukins (IL-6, IL-10), tumor necrosis factor
alpha (TNF-α), VEGF signal protein, and the decrease of IL-2 in me-
tastasis [16,17]. In one of our previous studies, the levels of cytokines
and growth factors were lower at the early stage prostate cancer pa-
tients than the one in the controls. Furthermore, remarkable diﬀerences
were found in the results of bound formaldehyde (HCHO), Zn-proto-
porphyrin and free protoporphyrin in erythrocytes of taxane-treated
metastatic, histologically negative and positive patients compared to
the healthy controls [18]. These ﬁndings are not only important in the
process of DNA hypomethylation because it could lead to high mutation
rate in most cases [19], but they are also in strong connection with the
redox status [20].
On the other hand, it was also demonstrated that not only the metal
elements could assist the absorption of vitamin D3 but conversely, the
uptake of micro and macronutrients (e.g., Ca, Mg, Cu, Zn, Fe, Se), and
certain transition metals might be facilitated by vitamin D3 in the
gastrointestinal tract in healthy individuals [21]. Even the absorption of
heavy metals can be assisted by vitamin D3. For that reason, despite the
beneﬁcial eﬀects of vitamin D3, heavy metal accumulation needs to be
taken into account, since the absorption of non-essential metal elements
could be aﬀected by the vitamin D3 intake in human [22]. It was also
demonstrated that the metal element status alters in the case of prostate
cancer with special emphasis on the Pb level [23], but there is no study
for investigating the metal element status in the function of vitamin D3
supplementation in prostate cancer.
Vitamin D3 deﬁciency could be a risk factor for prostate cancer in
the Hungarian man population since the vitamin D3 is lower than the
optimal level in 50% of the Hungarian population even in the summer
period [24]. There is no information available in the literature about
that how vitamin D3 treatment eﬀects on the metal element and redox
homeostasis in prostate cancer patients. Therefore, in the current study
our aim was to perform a comprehensive investigation on how vitamin
D3 supplementation in patient control and prostate cancer patients in-
ﬂuences the metal element- and redox homeostasis after a three-year
treatment.
2. Materials and methods
2.1. Materials
Vitamin D3 was a general consumer product on sale in the phar-
macy. Each gelatine capsule contained 3000–3300 IU (75–82.5 μg)
cholecalciferol (vitamin D3). Standard solutions, nitric acid, and hy-
drogen chloride were purchased from Reanal (Budapest). 1,1-diphenyl-
2-picrylhydrazyl, stable radical, hydrogen peroxide, luminol, micro-
peroxidase were obtained from Sigma (St. Luis). Spectro multi-element
standard solutions were used for ICP (CPAchem; Stara Zagora,
Bulgaria). The CHR hemoglobin reagent solution was purchased from
Reagents Ltd., Hungary.
2.2. Patients
42 volunteers with a mean age of 62.1 ± 15.9 years were ex-
amined, of which 25 were the outpatients of the Medical Centre of
Dunakeszi and 17 from the Department of Urology and Urooncological
Centre at the Semmelweis University, Budapest Hungary. The grouping
was executed by the treating physician according to cancer's pro-
gressivity (PSA, digital rectal examination, biopsy) and the vitamin D3
treatment. Harmful habits and other comorbidities of some patients
(smoking, alcohol consumption, diabetes mellitus, another type of
cancers) were considered. Conforming to the latter, two patients had to
be excluded from the investigation. Patients with vitamin D3 treated
groups received vitamin D3 treatment for three years continuously
under strict physician control.
The diet of the patients didn’t alter from the conventional
Hungarian dietary, the intake of vitamin D3 was 2.5 μg/day in men and
1.9 μg/day in women of 35–64 years old, while Ca was 759mg/day in
men and 690mg/day in women; Cu was 1.18mg/day in men and
0.94mg/day in women; and Zn was 9.65mg/day in men and 7.31mg/
day in women [24]. According to their state, they were following a
normal diet without taking any food supplements. The patients didn’t
work under extreme conditions and they weren’t exposed to any metal
toxicity (foundries, battery recycling, etc.). Blood samples were col-
lected in spring (March-April) after the three-year treatment. The pa-
tients were divided into 5 groups according to the Table 1:
Table 1
PSA level (μg/L) in diﬀerent patients’ groups after three-year treatment.
Patients PSA (μg/L)
Patient control group (N=8) 1.11 ± 0.45
Patient control group with vitamin D3 treatment (N=9) 0.75 ± 0.40
High-risk prostate cancer group (N=6) 13.0 ± 5.4*
High-risk prostate cancer group with vitamin D3 (N=8) 5.68 ± 1.11*,**
Vitamin D3 treated cancerous group with androgen
deprivation therapy (N=11)
1.40 ± 2.44**
* signiﬁcant diﬀerence to the patient control p < 0.01.
** signiﬁcant diﬀerence to the high-risk prostate cancer without vitamin D3
treatment p < 0.01.
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a patient control group (N=8 PSA < 2 μg/L); a patient control
group with vitamin D3 treatment (N=9; PSA < 2 μg/L); a high risk
prostate cancer group (N=6, PSA > 9 μg/L); a high risk prostate
cancer group with vitamin D3 treatment (N= 8; PSA > 4.1 μg/L) and
a cancerous group with vitamin D3 treatment who went under androgen
deprivation therapy (N=11, PSA < 9 μg/L).
The prognosis of the prostate cancer was determined according to
the PSA values, the digital rectal examination, and the biopsy results.
Into the patient control group those patients were classiﬁed whose PSA
value was under 2 μg/L, their digital rectal examination didn’t show
any inﬂammation or benign enlargement on the prostate and who
therefore weren’t suggested to have further biopsy examination.
Into the high-risk prostate cancer group those patients were classi-
ﬁed whose PSA value was higher than 2, even higher than 4.1 μg/L,
furthermore, their digital rectal examination showed some in-
ﬂammatory signs or enlargement on the prostate. They were also sent to
biopsy but the results came out negative.
Patients, whose cancer condition was rated with a Gleason score,
according to the anamnesis, were declared as the cancerous group.
They were 1–2 stadium prostate cancer patients, their tumor didn't
spread aggressively, and it didn't break through the tissue of the pros-
tate. In their case, androgen deprivation therapy (Firmagon, Eligard,
Bikalutam, Tamsulosin, Soladex, Diﬀerelin) was suﬃcient therefore
chemotherapy, or radiotherapy was not necessarily needed.
2.3. Vitamin D3 dosage
The 25-OH-D3 level in blood was adjusted by a therapist to about
100–150 nmol/L (40–60 ng/mL). Each patient received individually
1000–9000 IU vitamin D3 in a daily intake. After determining the 25-
hydroxyvitamin D level in the blood, the patients continuously received
the vitamin D3 treatment for three years before this study started. The
ordered amount was determined according to the estimated BMI value
and their health condition. The occasionally occurring vitamin D3 re-
sistance was also taken into account. The most accurate adjustment of
vitamin D3 level was achieved in the high-risk prostate cancer group
(Table 2), due to the fresh diagnosis and the patient's better compliance
with the vitamin D3 treatment. In most cases, the routine parameters
were normalized during the treatment, but unfortunately for 10–15% of
the patients, there was no improvement, which can be due to the low
VDR activity. In their case, Mg supplementation and a higher dose of
vitamin D3 helped to bring vitamin D3 in their blood to a normal level.
Further medical interventions would be needed in the cases of receptor
disorders or vitamin D3 resistance. According to the body weight,
medical treatment or other diseases, the vitamin D3 treatment was
sustainable with daily 1000 IU and rarely 9000 IU. Before the de-
termination of the proper vitamin D3 dosage for each patient, the
cholecalciferol level was measured in blood that was within 10–50 ng/
mL (25–125 nmol/L). The study was accomplished in accordance with
the ethical permissions, which was obtained from the Hungarian
Medical Research Council (Permission number: TUKEB 167/1997. 15/
2004) and the Institutional Review Board of the Semmelweis University
(Permission number: IKEB 3944/2004.). According to the physiological
data under 5 ng/ml (12.5 nmol/L) vitamin D3 level is considered to be
deﬁcient, between 10–20 ng/mL (25–50 nmol/L) low and the normal
range is between 28 and 80 ng/mL (70–200 nmol/L) [25,26]. The vi-
tamin D3 level was within the normal range in the vitamin D3 treated
groups and the patient control group, but in the high-risk prostate
cancer group (N=6) without vitamin D3 treatment it was in the low
range (Table 2).
2.4. Preparation of blood samples
After three-year treatment blood samples were collected in 3.2%
sodium citrate anticoagulant Vacutainer tubes (Greiner Bio-One,
Hungary of Vacutainer, USA) and were stored at 4 °C. They were pre-
pared with standard routine laboratory methods. The erythrocytes were
separated from plasma and buﬀy coat by centrifugation at 2500 rpm for
10min. The separation of the blood was started within 1.5 h after blood
collection. The buﬀy coat suspension was removed from the blood to
avoid its bias eﬀect while activating free radical reactions.
Subsequently, the erythrocyte was washed with isotonic saline solution
twice, and 20 μl of the raw fraction was standardized to 1% hemoglobin
with CHR Haemoglobin reagent. For hemoglobin determination, the
absorbance was measured at 540 nm on a Hitachi U-2000 spectro-
photometer. After blood separation and hemoglobin standardization
process the redox parameter measurements and the metal element
analysis were started.
2.5. Measurement of routine laboratory parameters
The laboratory parameters (hematology, immunochemical para-
meters, tumor markers) were measured by Synlab Hungary Kft, after
the three-year treatment when the blood was taken. The monitoring of
the vitamin D3 treatment was accomplished by the measurement of 25-
(OH) D3 vitamin/cholecalciferol in sera among the laboratory para-
meters. The determination of routine laboratory parameters was per-
formed with automatized laboratory instruments in ISO 9001:2008
environment. The following laboratory parameters were measured in
blood: glutamic-oxaloacetic transaminase/aspartate transaminase
(AST/GOT), glutamic-pyruvic transaminase/alanine transaminase
(ALT/GPT), gamma-glutamyl transferase (GGT), uric acid (UA), cho-
lesterol (Chol), creatinine (CREA), lactate dehydrogenase (LDH), hae-
moglobin (HGB), mean corpuscular volume (MCV), C-reactive protein
(CRP), prostate-speciﬁc antigen (PSA), free prostate speciﬁc antigen
(fPSA), white blood cell (WBC). Carcinoembryonic antigen (CEA) was
measured from serum with LIA-Mat immuno-luminometry (Budapest)
kits.
Most of the laboratory parameters were within the normal range,
and there were no signiﬁcant diﬀerences between the groups, which
can be due to the adequate medical treatment. Therefore these data
were omitted from the results part. There was no remarkable diﬀerence
in the cancerous groups in the liver parameters (GGT, GOT, GPT),
creatinine and MVC parameters. Cholesterol and leukocyte were 14%
and 20% higher in the high-risk cancerous group without vitamin D3
treatment, and triglyceride was 33% higher in the vitamin D3 treated
high-risk cancerous group compared to the control. The level of CRP
and CEA should give information about inﬂammation or the presence of
tumor in the body. Despite that in our result, the value of CRP and CEA
didn't exceed the normal level, and neither was much diﬀerence be-
tween groups which can be due to the patients' appropriate treatment.
The PSA level should be considered abnormal above 4.1 (μg/L). In
the high-risk prostate cancer group who didn't receive either vitamin D3
or androgen deprivation therapy, the PSA level was signiﬁcantly high
compared to the vitamin D3 treated group of which PSA value was
closer to the normal range but still high (Table 1). In these groups, the
digital rectal examination showed the mutation in the prostate size and
density, but the biopsy examination came out with negative results.
Table 2
D3 level (nmol/L) in patients’ group after three-year treatment.
Patients D3 vitamin level (nmol/L)
Patient control group (N=8) 74.3 ± 12.3
Patient control group with vitamin D3 treatment
(N=9)
99.2 ± 31.5
High-risk prostate cancer group (N=6) 36.6 ± 13.4
High-risk prostate cancer group with vitamin D3
(N=8)
116 ± 24
Vitamin D3 treated cancerous group with androgen
deprivation therapy (N=11)
133 ± 80
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2.6. Measurement of redox parameters
The hydrogen-donating ability in plasma was estimated in the pre-
sence of 1,1-diphenyl-2-picrylhydrazyl radical according to the method
of Hatano et al. [27] using Hitachi U-2000 spectrophotometer. The
results of the H-donating ability was calculated in inhibition percentage
(Inhib%). Induced chemiluminescence of the plasma and erythrocytes
was measured by a luminol-dependent chemiluminescence assay
(H2O2/OH·-microperoxidase-luminol-based system) according to the
method of Blázovics et al. [28]. This method was adapted to a Berthold
Lumat 9501 manual instrument (Berthold GmbH, Germany) [29]. The
results had been expressed as a relative light unit percentage (RLU%)
that is inversely proportional to the degree of scavenging capacity.
2.7. Measurements of micro and macro element concentration
The separated erythrocyte samples were measured on analytic bal-
ance then they were digested in the mixture of 10ml of HNO3 (65%),
2ml HCl (37%) and 4ml H2O2 (30%). The procedure was performed on
200 °C in block digester. The blind was prepared under the same con-
dition. After digestion of the samples, they were diluted with ion ex-
change water (17 MΩ, 28 °C; Purelab Ultra MK2. ULXXXI0M2 Model) to
25ml. Measurements were performed with a Spectro Genesis simulta-
neous ICP–OES spectrometer equipped with CCD detector (Kleve,
Germany) and axial plasma viewing [30].
The metal element concentrations in the bovine liver as Certiﬁed
Reference Material (Institute for Reference Materials and
Measurements, BCR®-185R) were determined for the demonstration of
reliability and precision of the measurement (Table 3). The recovery (R)
was calculated from the declared (DV) and measured values (MV) as
follows: R=MV/DV*100. In the case of most elements, which had no
certiﬁed values, the repeatability measurements were performed (ﬁve
times) with standard solutions of 0.5 μg/mL, 5 μg/mL, and 10 μg/mL
concentrations, and the recovery was calculated from these results
(Table 3).
2.8. Statistical analysis
The basic statistical analysis was prepared using Microsoft Oﬃce
Excel 2016 and Statistica 12 (StatSoft Inc., Tulsa. USA) software. To
verify distribution, Shapiro–Wilks test was used. The data had non-
parametric distribution. Therefore Mann–Whitney U test was used for
the comparison of groups. The signiﬁcance level was determined at
p<0.01. To calculate the correlation between data Spearman’s rank
correlations were used as they are more appropriate for not normal
distribution data than a linear correlation (e.g Pearson). Signiﬁcant
correlations were determined at p<0.05.
3. Results
There are signiﬁcant diﬀerences between the mean values of es-
sential and non-essential element concentrations measured in the
treated and non-treated groups as it is shown in Table 4. Interestingly,
the concentration of Pb was higher in the vitamin D3 treated patient
control and diseased groups than that of in the non-treated groups. The
diﬀerence was signiﬁcant (p<0.01) between the vitamin D3 treated
cancerous group and the non-treated high-risk cancerous patients. Si-
milar tendency could be observed in the Ca concentration, which was
also elevated in the vitamin D3 treated groups compared to the groups
without vitamin D3 administration. In addition, the Ca concentration
level in the vitamin D3 treated high-risk cancerous and cancerous
groups approached the control value. A signiﬁcant diﬀerence
(p<0.01) could be observed between the vitamin D3 supplemented
patient control individuals compared to the control group.
The study also demonstrates that the Cr (p<0.01) level was sig-
niﬁcantly higher in the vitamin D3 treated patient control and diseased
groups than that of in the groups without vitamin D3 administration.
Other metal elements such as B, Co, Fe, Mg, Mn, Ti, V, and Zn re-
presented a similar tendency to the previous results, with higher con-
centration in the vitamin D3 treated patient control and cancerous
groups. The Fe, Mg, Mn and Zn concentrations were remarkably higher
in the vitamin D3 treated groups compared to the non-treated ones. In
the Fe level signiﬁcant diﬀerence (p<0.01) was found between the
cancerous group with vitamin D3 treatment and the non-treated high-
risk cancerous group (Table 4). The concentration of Ni, Ca, Cr seemed
to be signiﬁcantly higher (p<0.01) in the patient control group with
vitamin D3 administration than that of in the patient control without
treatment.
The concentration of Cu and Li showed the opposite tendency to the
previously mentioned metals because in the vitamin D3 treated patient
control and diseased groups the concentration of Cu and Li was lower
than that of in the non-treated ones. A signiﬁcant diﬀerence was found
in the Cu concentration (p<0.01) between the high-risk cancerous
group and the vitamin D3 treated cancerous group who received an-
drogen deprivation therapy. The results also present that, despite the
lower Cu concentration in the vitamin D3 treated groups; its level is
close to the control value in the vitamin D3 treated high-risk prostate
cancer group (Table 4), as it was also observed by the Ca concentration.
In the results of the redox parameters measured in plasma, a lower
value (RLU%) could be observed in the vitamin D3 treated patient
control group compared to the non-treated patient control, which re-
ﬂects higher scavenging capacity in the supplemented group (Table 5).
That diﬀerence was more pronounced in the cancerous and high-risk
cancerous groups while the RLU% results were lower and the RLU% in
the cancerous group was signiﬁcantly lower, compared to the non-
treated high-risk cancer group, which indicates higher scavenging ca-
pacity in the treated groups. In erythrocyte, the induced chemilumi-
nescence was found to have an opposite tendency to the plasma results.
In the vitamin D3 treated groups the RLU% results were higher than
that of in the control group, which implies low free radical scavenging
capacity in patient control and diseased groups too. The diﬀerence was
signiﬁcant (p < 0.01) between the vitamin D3 treated diseased groups
and the non-treated high-risk cancerous group (Table 5).
The outcome of the results of the H-donating ability in plasma was
higher in the vitamin D3 treated groups both in patient control and
prostate cancer patients (Table 5), as it was expected from the
Table 3
Element concentration in reference material (Bovine liver Certiﬁed Reference
Material, BCR®-185R) and standard solution, as well as the measured values
with their recovery data.
Elements Certiﬁed
value
(μg/g)
Concentration of
standard solution (μg/
mL)
Measured value
(μg/g and μg/mL)
(N=5)
Recovery
(%)
Al 0.5 0.502 ± 0.002 100
B 0.5 0.503 ± 0.006 101
Ba 0.5 0.501 ± 0.002 100
Ca 10 9.99 ± 0.04 99.9
Cd 0.544 0.534 ± 0.027 98.2
Co 0.5 0.500 ± 0.002 100
Cr 0.5 0.497 ± 0.001 97.5
Cu 277 279 ± 6 99.4
Fe 10 9.99 ± 0.04 99.9
Li 0.5 0.501 ± 0.005 100
Mg 0.5 0.510 ± 0.002 102
Mn 11.07 10.8 ± 0.6 97.6
Ni 0.5 0.498 ± 0.006 99.6
P 50 49.9 ± 0.5 99.8
Pb 0.172 0.171 ± 0.006 99.4
S 50 50.5 ± 0.6 101
Sr 0.5 0.502 ± 0.003 100
Ti 10 9.99 ± 0.052 99.9
V 0.5 0.498 ± 0.007 99.6
Zn 138.6 140 ± 6 101
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scavenging capacity results.
4. Discussion
Vitamin D3 is an important vitamin for treatment against prostate
cancer due to its probable protective eﬀect against tumorigenesis
[9,10,31,32]. In this study, the eﬀect of vitamin D3 on prostate cancer
and its eﬀect on the metal element- and redox homeostasis in patient
control and diseased individuals were studied.
The PSA results (Table 1) show low values in the vitamin D3 treated
patient control and diseased groups. The vitamin D3 level (Table 2) and
the induced chemiluminescence in plasma (Table 5) show an adverse
tendency that might refer to free radical scavenging contribution of
vitamin D3.
Signiﬁcantly higher Pb concentration was found in the vitamin D3
treated cancerous groups compared to the non-treated groups. In early
and advanced stage prostate cancer other heavy metals tend to accu-
mulate which was established by other investigations as well [33]. So
far there are only a few studies that deal with the interaction between
vitamin D3 and Pb. Although, Ca absorption and metabolism are closely
associated with vitamin D3 [34] since Ca and vitamin D3 interacts in
many enzymatic pathways as it has a regulatory role in the Ca meta-
bolism. Ca uptake is stimulated by vitamin D3 [35] and Ca is built into
the bone's structure with the intervention of vitamin D3 [36]. One
would expect that in all treated groups the level of Ca should be in-
creased in red blood cells, but in this experiment Ca level was sig-
niﬁcantly elevated only in the patient control group. The large standard
deviation can be explained by the patients' diverse eating habits. This
result needs to awake more attention while the high Ca concentration in
the healthy body might lead to hypercalcemia which is among the
adverse consequences of vitamin D3 overdose.
The metabolism of Ca and Pb relates at many points in their
homeostasis, and they compete for the same calcium binding sites
[37–39]. It is known that Pb has a greater aﬃnity to calcium binding
proteins. Therefore small quantities of Pb can replace Ca [40]. Al-
though, the interaction between Pb and vitamin D3 biosynthesis is
underway to be clariﬁed [38], Pb accumulation in the erythrocyte is
suspected to eﬀect on vitamin D3 metabolism. It has been scientiﬁcally
proven that the controlled concentration of metals is essential for the
normal function of the enzymes and transcription factors.
Higher Cu level, as well as lower Fe and Zn concentration, were
detected in early-stage prostate cancer patients who didn't receive vi-
tamin D3 or androgen deprivation treatment compared to the control
group that is in agreement with some studies in the literature of pros-
tate cancer patients [41,42]. The metal element homeostasis change in
cancer refers to diﬀerent essential microelements and heavy metal
status in the body. The abnormally elevated level of heavy metals and
the accumulation or deﬁciency of some essential transition metals such
as Co, Cu, and Fe, could also be a responsible factor for the impairment
of receptor functions and enzymes activity such as tyrosine kinases
[43]. It adversely aﬀects signal molecules such as EGF, PDGF, VEGF,
NF-κB, AP-1, p53, NFAT and HIF-1 [44]. Fe deﬁciency can be a reason
for anemia in cancer [45]. These metal elements showed higher con-
centration in the vitamin D3 treated groups in the recent study. How-
ever, the level of Fe was elevated in the vitamin D3 treatment both in
patient control and diseased individuals, this result strengthens an
Table 4
Metal element concentration ± standard deviation (μg/g) in erythrocyte after three-year treatment.
Elements Patient control group
(N=8)
Patient control group with
vitamin D3 treatment (N=9)
High-risk prostate cancer
group (N=6)
High-risk prostate cancer group
with vitamin D3 (N=8)
Vitamin D3 treated cancerous group with
androgen deprivation therapy (N=11)
Al < 0.058 <0.058 <0.058 <0.058 <0.058
B 4.57 ± 5.89 6.18 ± 3.106 2.39 ± 2.42 7.04 ± 1.97 9.39 ± 5.05
Ba 0.447 ± 0.273 0.245 ± 0.172 0.316 ± 0.311 0.115 ± 0.149 0.113 ± 0.136
Ca 2.84 ± 2.36 4.32 ± 0.99* 2.44 ± 1.91 2.94 ± 1.79 3.32 ± 1.46
Co <0.004 0.057 ± 0.024 <0.004 0.012 ± 0.01 0.005 ± 0.002
Cr 0.044 ± 0.029 0.101 ± 0.056* 0.026 ± 0.015 0.097 ± 0.025** 0.097 ± 0.038**
Cu 0.054 ± 0.048 0.021 ± 0.014 0.080 ± 0.042 0.043 ± 0.060 0.027 ± 0.025**
Fe 29.0 ± 4.9 35.0 ± 5.1 24.8 ± 5.9 37.2 ± 3.9 34.9 ± 3.4**
Li 0.106 ± 0.087 0.006 ± 0.004 0.113 ± 0.061 0.007 ± 0.003 0.007 ± 0.004
Mg 1.67 ± 0.30 2.03 ± 1.04 1.29 ± 0.49 1.74 ± 0.28 1.74 ± 0.52
Mn 0.011 ± 0.007 0.033 ± 0.065 0.010 ± 0.010 0.013 ± 0.012 0.015 ± 0.015
Ni 0.051 ± 0.026 0.150 ± 0.050* 0.461 ± 0.500 0.170 ± 0.109 0.248 ± 0.304
P 14.1 ± 3.6 10.7 ± 2.7 12.1 ± 3.3 12.5 ± 3.3 10.5 ± 2.9
Pb 0.132 ± 0.046 0.197 ± 0.129 0.131 ± 0.053 0.723 ± 0.919 1.36 ± 0.78**
S 54.9 ± 1.7 51.3 ± 5.3 54.3 ± 2.8 55.2 ± 6.0 50.8 ± 4.2
Sr 0.027 ± 0.013 0.021 ± 0.033 0.023 ± 0.012 0.010 ± 0.014 0.012 ± 0.011
Ti 0.072 ± 0.069 0.776 ± 1.083 <0.004 0.216 ± 0.174 0.236 ± 0.294
V <0.031 0.047 ± 0.032 <0.031 0.042 ± 0.011 0.046 ± 0.011
Zn 0.372 ± 0.082 0.518 ± 0.259 0.307 ± 0.132 0.521 ± 0.173 0.436 ± 0.215
* signiﬁcant diﬀerence to the patient control p < 0.01.
** signiﬁcant diﬀerence to the high risk prostate cancer without vitamin D3 treatment p < 0.01.
Table 5
Redox parameters in erythrocyte after three-year treatment.
Patients Induced chemiluminescence in plasma
(RLU%)
Induced chemiluminescence in erythrocyte
(RLU%)
H-donating ability
in plasma
(inhibition%)
Patient control group (N=8) 144 ± 157 144 ± 46 63.6 ± 12.5
Patient control group with vitamin D3 treatment (N=9) 105 ± 122 177 ± 39 72.0 ± 4.2
High-risk prostate cancer group (N=6) 217 ± 179 125 ± 23 62.8 ± 14.0
High-risk prostate cancer group with vitamin D3 (N=8) 71 ± 40 156 ± 57** 75.5 ± 12.5**
Vitamin D3 treated cancerous group with androgen deprivation
therapy (N=11)
71 ± 49** 170 ± 70** 69.2 ± 9.9
** signiﬁcant diﬀerence to the high-risk prostate cancer without vitamin D3 treatment p < 0.01.
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earlier experiment that vitamin D3 is needed to administer Fe uptake
into red blood cells [46]. Zn metabolism is speciﬁc in prostate cancer
since in malign prostate cells Zn level was found to be signiﬁcantly low
[47–49] and it has been established that Zn depletion in the prostate’s
peripheral zone correlates with the Gleason score [33]. The higher Zn
level can be favorable since Zn is an important microelement in the
immune processes by protecting the erythrocytes against oxidative
stress [50]. However, the high ratio of Zn/Fe can assist the red blood
cells against the free radical load in prostate cancers progression. In our
results, the Zn/Fe ratio was reduced in the early stage prostate cancer
group who did not receive any treatment, however in the vitamin D3
treated patient control group and high-risk cancerous groups the Zn/Fe
ratio was higher, that was caused by the higher Zn concentration in the
erythrocyte. Signiﬁcantly elevated Zn-protoporphyrin concentration
can be observed in erythrocytes in cancerous processes which is very
important in cancer-associated anemia.[51].
The patients who received vitamin D3 treatment had signiﬁcantly
high Cr level both in patient control and diseased population. In the
literature so far there were very few investigations about the role of Cr
in prostate cancer or the importance of vitamin D3 in the Cr metabo-
lism, however, in our results, the signiﬁcant diﬀerences are shown
between the treated and non-treated groups. Cr is an important factor in
the glucose metabolism through a low molecular weight chromium
(LMWCr)-binding substance [52]. As it is already established that glu-
cose induces cell proliferation in prostate cancer [53], our result should
bring up more questions about the eﬀect of Cr in prostate cancer and of
vitamin D3 on Cr metabolism.
There are some non-signiﬁcant changes for elements nevertheless
their tendency can show valuable information. For example, the level of
Mg was elevated in the vitamin D3 treated groups which are in ac-
cordance with previous studies, where increased Mg absorption was
observed after a pharmacological dose of vitamin D3 supplementation
[54,55]. However, Mg also eﬀects on vitamin D3 metabolism that en-
ables binding to the vitamin D3 transporter protein and facilitates the
hydroxylation of vitamin D3 to be converted into its active form in the
liver and kidney [56]. Nevertheless, the role of Mg in prostate cancer
needs further investigations.
Ni concentration was high in the untreated high-risk prostate cancer
group but in the vitamin D3 treated and the control groups the Ni
concentration was low. The role of Ni in prostate cancer and of vitamin
D3 in Ni metabolism hasn’t been clariﬁed yet. According to the litera-
ture, the competition between Ni and Mg in the DNA repair mechanism
has been already discovered [54,57], but there are still no results in-
vestigating the interaction of these two metals in prostate cancer and
how vitamin D3 has an inﬂuence on their metabolism in normal or even
in diseased conditions. According to our results, there might be a
connection in the metabolism of the vitamin D3 and Ni, that could be
beneﬁcial, as Ni concentration approaches the control values that could
also be observed by Ca, Cu, Mn and Mg values too.
It seems from our results that in the groups with vitamin D3 treat-
ment the Li level was lower in erythrocyte. This could be a dangerous
side eﬀect as Li deﬁciency can lead to neurologic diseases [58] through
the inhibition of the signal transduction of phosphoinositide cycle by
reducing the cellular level of inositol which is linked to memory im-
pairment and depression [59]. Li may protect against oxidative stress,
which occurs during neurologic defects, by up-regulating the NADH
dehydrogenase and the cytochrome b-c1 complexes of the mitochon-
drial electron transport chain [59]. There is little data available in the
literature about the role of Li in prostate cancer. Its anti-cancer po-
tential was investigated and it was established that Li inhibits the gly-
cogen synthase kinase 3 (GSK-3) action, that’s activation is associated
with the prostate cancer’s progression [60].
We found lower induced chemiluminescence in the plasma (Table 5)
of vitamin D3 treated patient control and cancerous individuals com-
pared to the patient control and cancerous group without treatment
that could refer to higher free radical scavenging capacity in those
groups. The results of redox parameters allow us to suppose that the
permanent vitamin D3 intake aﬀects the redox homeostasis through its
metabolism in the diseased environment and normal conditions, too.
The diﬀerences between patient control groups with and without vi-
tamin D3 administration proposes the question whether the persistent
treatment of vitamin D3 is necessary with the current instructions.
Normally, in cancer, the free radical scavenging capacity is lower than
that of in the control groups, and it is usually elevated in the ﬁnal stage
of metastasis [61] that may show a connection to the vitamin D3 deﬁ-
ciency that could lead to the activation of glutathione-dependent en-
zymes [62].
The elevation of the inhibition% in plasma might be due to the
indirect concentration growth of those molecules which have an H-
donating capacity. It is assumed that vitamin D3 treatment has a po-
tential role in the inﬂammatory suppression processes.
The oxidative stress induction by the extended concentration of
certain metal elements is known and it is agreed with our results. The
free scavenging capacity in erythrocytes was lower in the groups where
a high concentration of Fe, Pb and Cr could be observed. Decreased Zn/
Fe ratio could be observed in the groups with high RLU%. The con-
centration of Zn was elevated in the groups where the antioxidant ca-
pacity was high. From the literature, it is already known that Zn assists
the immune strengthening processes that is possibly related to the
higher scavenging capacity and facilitates the absorption of vitamin D3
[63].
Signiﬁcantly positive (p < 0.05) correlations were found between
Table 6
Signiﬁcant correlation values (Spearman's rank correlation coeﬃcient) between the metal elements and redox parameters or PSA; and between the vitamin D3 level
and metal elements measured from erythrocyte (p < 0.05).
Patient control
group (N=8)
Patient control group with
vitamin D3 treatment (N=9)
High-risk prostate
cancer group (N=6)
High-risk prostate cancer
group with vitamin D3
(N=8)
Vitamin D3 treated cancerous group with
androgen deprivation therapy (N=11)
PSA-Fe 0.866
PSA-Mg 0.904
PSA-Sr 0.866 0.813
(RLU%) erythrocyte-Ba −0.809
(RLU%) erythrocyte-Cu −0.762 −0.673
(RLU%) erythrocyte-Li −0.786 −0.667
(RLU%) erythrocyte-
Mg
(RLU%) erythrocyte-
Mn
0.711 −0.775
(RLU%) erythrocyte-P −0.767
(RLU%) erythrocyte-Sr −0.755 −0.812
vitamin D3 level-B 0.821
vitamin D3 level-Mn 0.829
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the vitamin D3 level and metal concentrations in the vitamin D3 treated
patient control group and the vitamin D3 treated cancerous group
(Table 6). In the vitamin D3 treated patient control group the vitamin
D3 level correlated in a signiﬁcantly positive way with B level (+0.821)
and in the vitamin D3 treated cancerous group the vitamin D3 level
correlated in a signiﬁcantly positive way with the Mn level (+0.829).
In the other groups, there were no signiﬁcant correlations between the
metal elements and the vitamin D3 level.
We looked at correlations of the metal elements, the redox para-
meters and the PSA (Table 6). The correlations in the vitamin D3 treated
groups are diﬀerent to the correlations found in the control. We can
come to the conclusion that the vitamin D3 treatment obviously had an
eﬀect on the metal element- and the redox-homeostasis. In the high-risk
prostate cancer group with vitamin D3 treatment, there was no corre-
lation found, that can be by reason of a total homeostasis disorder. It is
not reﬂected on the metal elements but can be generated by a large-
scale change of the redox parameters. The positive correlation between
PSA and Fe suggests that the high Fe level could assist the increase of
PSA level.
5. Conclusion
According to our experiment vitamin D3 plays an essential role in
the inorganic elements level that can indicate its inﬂuence on the ele-
ment metabolism in prostate cancer. The metal element concentration
diﬀerence can further inﬂuence the overcome the disease. In the ery-
throcyte of patients with prostate cancer, the vitamin D3 treatment had
a positive eﬀect on the metabolism of the most important essential
elements as Ca, Cu, Mn, Mg and Ni because their concentration con-
verged to the control values. At the same time, the potential formation
of Li deﬁciency by the treatment of vitamin D3 in prostate cancer needs
further investigation.
From the induced chemiluminescence and H-donating ability re-
sults, it appears that the vitamin D3 treatment favorably aﬀected the
antioxidant system because we got consistently better results in the
patient control and cancerous groups. It is worth considering from our
results that, the diﬀerence was more expressed in the high-risk can-
cerous group with vitamin D3.
There is still no existing optimal factor for the prognosis of prostate
cancer. Therefore our results could be one further step to the feasible
diagnosis of prostate cancer. Besides, metal element status could be
another prognostic index in prostate adenocarcinoma to diﬀerentiate
between low and high-risk estate cancer's progression phases. The sig-
niﬁcant decrease of PSA with the increase of the scavenging capacity of
the treatment might be attributable to the beneﬁcial eﬀect of vitamin
D3 on the antioxidant system. However, further comprehensive in-
vestigations are required to understand the role of vitamin D3 on the
element status in prostate adenocarcinoma.
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